Correlation
The correlation between PAHC and BMY is 0.37, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
PAHC vs. BMY
Compare and contrast key facts about Phibro Animal Health Corporation (PAHC) and Bristol-Myers Squibb Company (BMY).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: PAHC or BMY.
Performance
PAHC vs. BMY - Performance Comparison
Loading data...
Key characteristics
PAHC:
0.85
BMY:
0.83
PAHC:
1.51
BMY:
1.38
PAHC:
1.18
BMY:
1.17
PAHC:
0.60
BMY:
0.53
PAHC:
2.96
BMY:
2.67
PAHC:
13.03%
BMY:
9.42%
PAHC:
48.00%
BMY:
31.39%
PAHC:
-79.60%
BMY:
-70.62%
PAHC:
-46.13%
BMY:
-33.83%
Fundamentals
PAHC:
$989.83M
BMY:
$98.25B
PAHC:
$0.78
BMY:
$2.70
PAHC:
31.31
BMY:
17.88
PAHC:
1.66
BMY:
2.26
PAHC:
0.83
BMY:
2.06
PAHC:
3.76
BMY:
5.60
PAHC:
$1.19B
BMY:
$47.64B
PAHC:
$376.71M
BMY:
$31.43B
PAHC:
$128.96M
BMY:
$16.18B
Returns By Period
In the year-to-date period, PAHC achieves a 16.87% return, which is significantly higher than BMY's -12.76% return. Over the past 10 years, PAHC has underperformed BMY with an annualized return of -1.24%, while BMY has yielded a comparatively higher 0.11% annualized return.
PAHC
16.87%
31.29%
5.02%
41.75%
11.53%
1.32%
-1.24%
BMY
-12.76%
-2.68%
-16.68%
23.27%
-10.29%
-0.59%
0.11%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
PAHC vs. BMY — Risk-Adjusted Performance Rank
PAHC
BMY
PAHC vs. BMY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Phibro Animal Health Corporation (PAHC) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
PAHC vs. BMY - Dividend Comparison
PAHC's dividend yield for the trailing twelve months is around 1.97%, less than BMY's 5.05% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
PAHC Phibro Animal Health Corporation | 1.97% | 2.29% | 4.15% | 3.58% | 2.35% | 2.47% | 1.93% | 1.31% | 1.19% | 1.37% | 1.33% | 0.63% |
BMY Bristol-Myers Squibb Company | 5.05% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% | 2.46% |
Drawdowns
PAHC vs. BMY - Drawdown Comparison
The maximum PAHC drawdown since its inception was -79.60%, which is greater than BMY's maximum drawdown of -70.62%. Use the drawdown chart below to compare losses from any high point for PAHC and BMY.
Loading data...
Volatility
PAHC vs. BMY - Volatility Comparison
Phibro Animal Health Corporation (PAHC) has a higher volatility of 18.75% compared to Bristol-Myers Squibb Company (BMY) at 11.13%. This indicates that PAHC's price experiences larger fluctuations and is considered to be riskier than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
PAHC vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between Phibro Animal Health Corporation and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
PAHC vs. BMY - Profitability Comparison
PAHC - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2025, Phibro Animal Health Corporation reported a gross profit of 104.57M and revenue of 347.83M. Therefore, the gross margin over that period was 30.1%.
BMY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2025, Bristol-Myers Squibb Company reported a gross profit of 8.17B and revenue of 11.20B. Therefore, the gross margin over that period was 72.9%.
PAHC - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2025, Phibro Animal Health Corporation reported an operating income of 33.52M and revenue of 347.83M, resulting in an operating margin of 9.6%.
BMY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2025, Bristol-Myers Squibb Company reported an operating income of 3.52B and revenue of 11.20B, resulting in an operating margin of 31.4%.
PAHC - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2025, Phibro Animal Health Corporation reported a net income of 20.88M and revenue of 347.83M, resulting in a net margin of 6.0%.
BMY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2025, Bristol-Myers Squibb Company reported a net income of 2.46B and revenue of 11.20B, resulting in a net margin of 21.9%.